Tainuo Maibo's listing on the Science and Technology Innovation Board has been accepted. Its core product, TNM002, has been approved for listing in China.

On July 31, Zhuhai Tainuomaibo Pharmaceutical Co., Ltd. (referred to as "Tainuomaibo") submitted its application for an IPO on the SSE STAR Market. Huatai Securities is its sponsor and it plans to raise 1.5 billion yuan. According to the prospectus, Tainuomaibo was established in 2015 and is an innovative biopharmaceutical company dedicated to blood product replacement therapy for the global market. The company is guided by the principle of "creating clinical value" and adheres to a strategy of differentiation innovation and competition, focusing on the development, manufacturing, commercialization, and potential substitution of globally specific blood products with fully human monoclonal antibodies to meet a wide range of clinical needs and benefit patients. One of the company's core products, Stetagta monoclonal antibody injection (recombinant anti-tetanus toxin fully human monoclonal antibody TNM002, trade name: Xin Tituo), was approved for listing in China in February 2025, making it the world's first recombinant anti-tetanus toxin monoclonal antibody drug. It is designated by China CDE as a breakthrough therapy and included in the priority review program (also the first domestic innovative biopharmaceutical drug in the anti-infective field to be recognized as a breakthrough therapy), and has been granted Fast Track qualification by the US FDA, representing a global innovative significance in the field of tetanus prevention. Another core product of the company, Recombinant anti-respiratory syncytial virus fully human monoclonal antibody TNM001 (TNM001), is a potential global third and China's first long-acting preventive antibody drug for healthy and high-risk infants and young children. As of the date of the prospectus, TNM001 is undergoing Phase III clinical trials. The company's pipeline of research drugs all adopt fully human monoclonal antibody design, and currently two major drugs have demonstrated good safety and efficacy in clinical trials, providing outstanding differential competitive advantages in their respective fields. Furthermore, as of the date of the prospectus, the company has developed multiple antibody molecules as candidate drugs, covering infectious diseases, pain-related diseases, and other disease areas. Among them, the world's first Stetagta monoclonal antibody injection has been approved for listing, TNM001 (anti-respiratory syncytial virus RSV monoclonal antibody) is undergoing Phase III clinical trials, two candidate drugs, TNM009 (anti-nerve growth factor NGF monoclonal antibody) and TNM005 (anti-varicella-zoster virus VZV monoclonal antibody) have completed Phase I clinical trials, one candidate drug, TNM006 (anti-human cytomegalovirus HCMV monoclonal antibody) has received IND approval, and three candidate drugs are in the pre-clinical stage. Among the mentioned products, Stetagta monoclonal antibody injection and TNM005 are the world's first (First-in-Class) or have the potential to be the world's first, while TNM001 and TNM006 have the potential to be the first domestically produced drugs. The actual proceeds from the issuance of new shares in this offering, after deducting issuance expenses, will be used entirely for the company's main business-related projects and operating capital needed for the development of the main business. Specifically, the investment projects are as follows: Financially, in the 2022 fiscal year, 2023 fiscal year, 2024 fiscal year, and January-March 2025, the company achieved operating income of 4.3398 million yuan, 0 yuan, 15.0559 million yuan, and 1.693 million yuan, respectively. During the same period, the net profit was approximately -429 million yuan, -446 million yuan, -515 million yuan, and -177 million yuan, respectively.